A Phase I Clinical Trial of BAT4306F (for injection) on Safety, Tolerability and Pharmacokinetics for Patients with CD20-positive, B-cell non-Hodgkin's lymphoma
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs BAT-4306F (Primary)
- Indications Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Bio-Thera Solutions
- 16 Oct 2018 Status changed from planning to not yet recruiting.
- 05 Apr 2018 New trial record
- 30 Mar 2018 According to a Bio-Thera Solutions media release, this trial is anticipated to start during the second quarter of 2018.